Want to see KR:009290 full AI Analyst Report?
Top Page
Kwang Dong Pharmaceutical Co., Ltd.
(009290)
Select Model
Select Model
Rating:52Neutral
Price Target:
₩6,424.00
Action:N/A
Date:10/28/26
Overall score reflects pressured operating quality and volatile cash generation despite faster TTM revenue growth, which limits confidence in near-term fundamentals. Technicals also lean weak with price below major moving averages and soft momentum, partially offset by a reasonable valuation (P/E ~12.6) and modest dividend yield.
Positive Factors
Accelerating Revenue Growth
Faster TTM revenue growth indicates stronger recent demand across the company’s pharmaceutical and health-product portfolio. If sustained, this broader sales base can improve operating leverage, support channel strength, and provide a foundation for rebuilding profitability over the next several quarters.
Negative Factors
Thin and Recently Negative Margins
Very thin net margins leave limited earnings protection if costs rise or sales growth moderates. The shift to negative TTM operating and EBITDA margins is more concerning because it signals pressure in the core business, potentially limiting reinvestment, weakening resilience, and reducing the benefit of higher revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Faster TTM revenue growth indicates stronger recent demand across the company’s pharmaceutical and health-product portfolio. If sustained, this broader sales base can improve operating leverage, support channel strength, and provide a foundation for rebuilding profitability over the next several quarters.
Read all positive factors
Kwang Dong Pharmaceutical Co., Ltd. (009290) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩299.64B
Dividend Yield1.57%
Average Volume (3M)135.31K
Price to Earnings (P/E)12.6
Beta (1Y)0.18
Revenue Growth5.50%
EPS Growth-26.11%
CountryKR
Employees1,022
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)504.90
Shares Outstanding49,799,810
10 Day Avg. Volume131,854
30 Day Avg. Volume135,308
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.47
Price to Sales (P/S)0.19
P/FCF Ratio5.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kwang Dong Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Established in Seoul, South Korea, in 1963, Kwang Dong Pharmaceutical Co., Ltd. functions as a diversified healthcare enterprise. The company is actively involved in the development and distribution of an extensive range of pharmaceutical products...
Kwang Dong Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
68
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.71T | 1.66T | 1.64T | 1.51T | 1.43T | 1.34T |
| Gross Profit | 300.73B | 293.22B | 299.30B | 295.12B | 282.05B | 274.25B |
| EBITDA | -14.21B | 48.54B | 44.63B | 54.97B | 54.04B | 51.09B |
| Net Income | 21.82B | 20.97B | 40.48B | 36.97B | 24.17B | 24.02B |
Balance Sheet | ||||||
| Total Assets | 1.31T | 1.32T | 1.17T | 1.08T | 932.02B | 883.85B |
| Cash, Cash Equivalents and Short-Term Investments | 177.70B | 227.69B | 165.45B | 206.18B | 208.63B | 187.70B |
| Total Debt | 300.93B | 303.21B | 285.92B | 235.64B | 138.01B | 132.05B |
| Total Liabilities | 602.39B | 605.55B | 552.01B | 490.02B | 384.98B | 356.60B |
| Stockholders Equity | 638.67B | 655.58B | 579.12B | 544.62B | 517.33B | 499.18B |
Cash Flow | ||||||
| Free Cash Flow | 4.34B | 57.11B | -89.95B | -46.89B | 36.78B | 30.49B |
| Operating Cash Flow | 17.69B | 82.34B | -12.15B | -11.73B | 62.82B | 54.94B |
| Investing Cash Flow | -69.76B | -102.58B | 12.77B | -71.83B | -42.75B | -42.98B |
| Financing Cash Flow | 42.42B | 45.52B | 36.76B | 58.01B | -628.26M | 15.89B |
Kwang Dong Pharmaceutical Co., Ltd. Technical Analysis
Negative
―
Price Trends
6439.00
Negative
6242.30
Positive
6918.45
Negative
Market Momentum
5.61
Positive
42.51
Neutral
9.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:009290, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 6630.00, equal to the 50-day MA of 6439.00, and equal to the 200-day MA of 6918.45, indicating a bearish trend. The MACD of 5.61 indicates Positive momentum. The RSI at 42.51 is Neutral, neither overbought nor oversold. The STOCH value of 9.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:009290.
Kwang Dong Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩560.29B | 5.53 | ― | 2.80% | 10.50% | 96.29% | |
60 Neutral | ₩404.42B | 8.96 | ― | 1.56% | -0.65% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₩299.64B | 12.56 | ― | 1.57% | 5.50% | -26.11% | |
51 Neutral | ₩435.39B | -884.82 | ― | 0.08% | 6.21% | 95.65% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
46 Neutral | ₩332.73B | -56.26 | ― | 2.01% | 15.38% | ― |
* General Sector Average
KR:009290
Kwang Dong Pharmaceutical Co., Ltd.
6,370.00
705.94
12.46%
KR:001060
JW Pharmaceutical Corporation
23,200.00
533.84
2.36%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
177.39
4.97%
KR:019170
Shinpoong Pharmaceutical Co., Ltd.
8,460.00
-5,070.00
-37.47%
KR:170900
Dong-A ST Co., Ltd.
34,900.00
-9,625.21
-21.62%
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,790.00
-9,511.57
-42.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.